BR112022011344A2 - Compostos para tratamento de doença de alzheimer e uso desses compostos - Google Patents
Compostos para tratamento de doença de alzheimer e uso desses compostosInfo
- Publication number
- BR112022011344A2 BR112022011344A2 BR112022011344A BR112022011344A BR112022011344A2 BR 112022011344 A2 BR112022011344 A2 BR 112022011344A2 BR 112022011344 A BR112022011344 A BR 112022011344A BR 112022011344 A BR112022011344 A BR 112022011344A BR 112022011344 A2 BR112022011344 A2 BR 112022011344A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- disease
- alzheimer
- hydroxy
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 abstract 2
- SEBPXHSZHLFWRL-UHFFFAOYSA-N 3,4-dihydro-2,2,5,7,8-pentamethyl-2h-1-benzopyran-6-ol Chemical compound O1C(C)(C)CCC2=C1C(C)=C(C)C(O)=C2C SEBPXHSZHLFWRL-UHFFFAOYSA-N 0.000 abstract 2
- -1 6-hydroxy-2,5,7,8-tetramethylchroman-2yl Chemical group 0.000 abstract 2
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 abstract 2
- 125000000687 hydroquinonyl group Chemical class C1(O)=C(C=C(O)C=C1)* 0.000 abstract 1
- 230000006386 memory function Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- LZYWLEPSQNXESC-KUHUBIRLSA-N sonlicromanol Chemical compound O=C([C@@]1(C)OC=2C(C)=C(C(=C(C)C=2CC1)O)C)N[C@@H]1CCCNC1 LZYWLEPSQNXESC-KUHUBIRLSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
COMPOSTOS PARA TRATAMENTO DE DOENÇA DE ALZHEIMER E USO DESSES COMPOSTOS. A presente invenção refere-se a certos compostos de cromanol, quinona ou hidroquinona e derivados dos mesmos para tratamento da doença de Alzheimer e/ou para melhorar a função de memória e/ou reduzir a carga de placa. Especificamente, a presente invenção refere-se a compostos de cromanol escolhidos a partir de (6-hidróxi-2,5,7,8-tetrametilcroman-2il)(piperazin-1-5-il)metanona, cloridrato de ((S)-6-hidróxi-2,5,7,8-tetrametil-N-((R)-piperidin-3-il)croman-2-carboxamida e S-(6-hidróxi-2,5,7,8-tetrametilcroman-2-il)(4-(2-hidroxietil)piperazin-1-il)metanona e sais farmaceuticamente aceitáveis dos mesmos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2024431A NL2024431B1 (en) | 2019-12-11 | 2019-12-11 | Compounds for treatment of alzheimer’s disease |
| PCT/NL2020/050782 WO2021118359A1 (en) | 2019-12-11 | 2020-12-11 | Compounds for treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022011344A2 true BR112022011344A2 (pt) | 2022-08-23 |
Family
ID=69173381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022011344A BR112022011344A2 (pt) | 2019-12-11 | 2020-12-11 | Compostos para tratamento de doença de alzheimer e uso desses compostos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230052152A1 (pt) |
| EP (1) | EP4072550A1 (pt) |
| JP (1) | JP2023506480A (pt) |
| KR (1) | KR20220119032A (pt) |
| AU (1) | AU2020400823A1 (pt) |
| BR (1) | BR112022011344A2 (pt) |
| CA (1) | CA3164071A1 (pt) |
| CL (1) | CL2022001520A1 (pt) |
| IL (1) | IL293758A (pt) |
| JO (1) | JOP20220140A1 (pt) |
| MX (1) | MX2022007227A (pt) |
| NL (1) | NL2024431B1 (pt) |
| WO (1) | WO2021118359A1 (pt) |
| ZA (1) | ZA202206837B (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL2010010C2 (en) * | 2012-12-19 | 2014-06-23 | Sulfateq B V | Compounds for protection of cells. |
| NL2031091B1 (en) * | 2022-02-28 | 2023-09-07 | Sulfateq Bv | Chromanol compounds for treatment or prophylaxis of ageing and ageing-associated disorders |
| WO2024083822A1 (en) * | 2022-10-18 | 2024-04-25 | Immungenetics Ag | Identifying a subject suffering from alzheimer's dementia or being at risk of developing alzheimer's dementia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1339404A2 (en) * | 2000-10-31 | 2003-09-03 | Colgate-Palmolive Company | Composition and method |
| PL2157973T3 (pl) | 2007-05-22 | 2015-12-31 | Otsuka Pharma Co Ltd | Lek zawierający pochodną karbostyrylu i donepezil do leczenia choroby Alzheimera |
| MX2010004622A (es) * | 2007-11-06 | 2010-05-20 | Edison Pharmaceuticals Inc | Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales. |
| CA2878567C (en) | 2012-07-12 | 2021-02-23 | Khondrion Ip B.V. | Chromanyl derivatives for treating mitochondrial disease |
| JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
| NL2010010C2 (en) | 2012-12-19 | 2014-06-23 | Sulfateq B V | Compounds for protection of cells. |
| EP2994160B1 (en) | 2013-05-06 | 2019-07-03 | Baxalta Incorporated | Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g |
| US10815211B2 (en) | 2015-10-08 | 2020-10-27 | Khondrion Ip B.V. | Compounds for treating mitochondrial disease |
| EP3713564B1 (en) * | 2017-11-22 | 2023-11-15 | Khondrion Ip B.V. | Compounds as mpges-1 inhibitors |
-
2019
- 2019-12-11 NL NL2024431A patent/NL2024431B1/en active
-
2020
- 2020-12-11 KR KR1020227020822A patent/KR20220119032A/ko active Search and Examination
- 2020-12-11 JP JP2022535567A patent/JP2023506480A/ja active Pending
- 2020-12-11 JO JOP/2022/0140A patent/JOP20220140A1/ar unknown
- 2020-12-11 MX MX2022007227A patent/MX2022007227A/es unknown
- 2020-12-11 AU AU2020400823A patent/AU2020400823A1/en active Pending
- 2020-12-11 US US17/783,671 patent/US20230052152A1/en active Pending
- 2020-12-11 EP EP20828157.6A patent/EP4072550A1/en active Pending
- 2020-12-11 BR BR112022011344A patent/BR112022011344A2/pt unknown
- 2020-12-11 WO PCT/NL2020/050782 patent/WO2021118359A1/en active Application Filing
- 2020-12-11 CA CA3164071A patent/CA3164071A1/en active Pending
- 2020-12-11 IL IL293758A patent/IL293758A/en unknown
-
2022
- 2022-06-09 CL CL2022001520A patent/CL2022001520A1/es unknown
- 2022-06-20 ZA ZA2022/06837A patent/ZA202206837B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3164071A1 (en) | 2021-06-17 |
| ZA202206837B (en) | 2023-11-29 |
| NL2024431B1 (en) | 2021-09-07 |
| KR20220119032A (ko) | 2022-08-26 |
| US20230052152A1 (en) | 2023-02-16 |
| WO2021118359A1 (en) | 2021-06-17 |
| AU2020400823A1 (en) | 2022-06-23 |
| JP2023506480A (ja) | 2023-02-16 |
| CL2022001520A1 (es) | 2023-02-24 |
| MX2022007227A (es) | 2022-09-19 |
| EP4072550A1 (en) | 2022-10-19 |
| IL293758A (en) | 2022-08-01 |
| JOP20220140A1 (ar) | 2023-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022011344A2 (pt) | Compostos para tratamento de doença de alzheimer e uso desses compostos | |
| CY1121330T1 (el) | Συνθεσεις που περιλαμβανουν αζελαστινη και μεθοδοι χρησης αυτων | |
| EA201101668A1 (ru) | Редокс-активные терапевтические средства для лечения митохондриальных нарушений | |
| BRPI0416989A (pt) | derivados aminopirazole como inibidores gsk-3 | |
| EA200971086A1 (ru) | Фармацевтические композиции и способ лечения шизофрении | |
| NO20062181L (no) | Metode for fremstilling av aminokrotonylforbindelser | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| GT200500098A (es) | Nuevos compuestos | |
| BR0211742A (pt) | Derivados de aminoisoxazole ativos como inibidores de cinase | |
| EA200971069A1 (ru) | Метаболиты производных (тио)карбомоилциклогексана | |
| NO20080284L (no) | Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer | |
| BR0212378A (pt) | Inibidores de 17beta-hidroxiesteróide desidrogenase tipo 3 para o tratamento de doenças dependentes de androgênio | |
| UA102517C2 (ru) | Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы | |
| BR0317572A (pt) | Benzoxazinas e seus derivados como inibidores de pi3ks | |
| NO20061743L (no) | Kinazolinderivater | |
| BR112023022580A2 (pt) | Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças | |
| DE59907752D1 (de) | Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien | |
| BR0214177A (pt) | Derivado de benzofenona, agente preventivo ou terapêutico para uma doença em que está envolvida expressão excessiva de ap-1, e, inibidor de ap-1 | |
| BR112019025214A2 (pt) | Composição farmacêutica sólida administrável por via oral, uso da composição farmacêutica, processo para a preparação de composições farmacêuticas, e, método de tratamento de um paciente que sofre de condições patológicas | |
| EA200601194A1 (ru) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором | |
| CL2023000800A1 (es) | Compuestos de cromanol para el tratamiento de la insuficiencia cardíaca | |
| ATE409480T1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
| ATE541567T1 (de) | Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten | |
| ATE403428T1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
| NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser |